EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial

Karim Fizazi iD, Gwénaël Le Teuff iD, Aude Fléchon, Lance Pagliaro, Josef Mardiak, Lionnel Geoffrois, Brigitte Laguerre, Christine Chevreau, Remy Delva, Frederic Rolland iD, Christine Theodore, Guilhem Roubaud und 8 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.01960 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Karim Fizazi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Bleomycin, Cisplatin. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. GETUG-13 established that switching patients with poor-prognosis nonseminomatous germ-cell tumors with an unfavorable marker decline to intensified chemotherapy resulted in improved outcomes. Here, we report the GETUG-13 long-term efficacy and toxicity. Two hundred and sixty-three patients with International Germ Cell Cancer Consensus Group poor prognosis received one cycle of bleomycin, etoposide, and cisplatin (BEP): 51 with a favorable tumor marker decline continued with three cycles of BEP (Fav-BEP) and 203 with an unfavorable decline were randomly treated with three BEP (Unfav-BEP) cycles or a dose-dense regimen (Unfav-dose-dense; two cycles of paclitaxel-BEP-oxaliplatin + two cycles of cisplatin, ifosfamide, and bleomycin). The median follow-up was 7.1 years (range, 0.3-13.3). Five-year progression-free survival (PFS) rates were 58.9% in the Unfav-dose-dense arm and 46.7% in the Unfav-BEP arm (hazard ratio [HR], 0.65 [95% CI, 0.44 to 0.97]; P = .036). Five-year overall survival rates were 70.9% and 61.3% (HR, 0.74 [95% CI, 0.46 to 1.20]; P = .22). Side effects evolved favorably, with only three patients in the Unfav-dose-dense arm reporting grade 3 motor neurotoxicity at 1 year and no reported toxicity over grade 1 after year 2. Salvage high-dose chemotherapy plus a stem-cell transplant was used in 8% in the Unfav-dose-dense arm and 17% in the Unfav-BEP arm ( P = .035). Long-term outcomes suggest a sustained benefit of intensified chemotherapy in terms of PFS and numerically better survival, with a minimal toxicity and reduced use of salvage high-dose chemotherapy plus stem-cell transplant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinCisplatinEtoposideNeoplasms, Germ Cell and EmbryonalAdolescentAdultHumansMaleMiddle AgedYoung AdultOxaliplatinPaclitaxelPrecision MedicinePrognosisTesticular Neoplasms

Substanzen

Biomarkers, TumorBleomycinCisplatinEtoposideOxaliplatinPaclitaxel

Autor:innen und Institutionen

  • Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
  • CESP U1018, Oncostat, labeled Ligue Contre le Cancer, University of Paris Saclay, Villejuif, France.
  • Department of Biostatistics, Institut Gustave Roussy, Villejuif, France.
  • Department of Cancer Medicine, Centre Léon Bérard, Lyon, France.
  • UT MD Anderson Cancer Center, Houston, TX.
  • National Cancer Institute, Bratislava, Slovakia.

ORCID-Profile: Karim Fizazi, Gwénaël Le Teuff, Frederic Rolland, Gwenaëlle Gravis, Mathilde Cancel, Maria Reckova, Natacha Naoun, Stephane Culine

Zitieren

APA

Fizazi, K., Le Teuff, G., Fléchon, A., Pagliaro, L., Mardiak, J., Geoffrois, L., Laguerre, B., Chevreau, C., Delva, R., Rolland, F., Theodore, C., Roubaud, G., Gravis, G., Eymard, J. C., Cancel, M., Juzyna, B., Reckova, M., Naoun, N., Logothetis, C., & Culine, S. (2024). Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01960

Vancouver

Fizazi K, Le Teuff G, Fléchon A, Pagliaro L, Mardiak J, Geoffrois L, et al. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01960

BibTeX
@article{Fizazi2024,
  author = {Fizazi, Karim and Le Teuff, Gwénaël and Fléchon, Aude and Pagliaro, Lance and Mardiak, Josef and Geoffrois, Lionnel and Laguerre, Brigitte and Chevreau, Christine and Delva, Remy and Rolland, Frederic and Theodore, Christine and Roubaud, Guilhem and Gravis, Gwenaëlle and Eymard, Jean-Christophe and Cancel, Mathilde and Juzyna, Beata and Reckova, Maria and Naoun, Natacha and Logothetis, Christopher and Culine, Stephane},
  title = {Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.01960}
}
Kostenlos starten →